Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Rigosertib |
Synonyms | |
Therapy Description |
ON01910 is a small molecule inhibitor of Plk1, resulting in mitotic cell-cycle arrest and inhibition of tumor growth (PMID: 15766665). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rigosertib | ON01910 | PLK1 Inhibitor 16 | Rigosertib (ON01910) is a small molecule inhibitor of Plk1, resulting in mitotic cell-cycle arrest and inhibition of tumor growth (PMID: 15766665, PMID: 32442785). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | Advanced Solid Tumor | sensitive | Rigosertib | Preclinical - Cell culture | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited viability of transformed cells expressing BRAF V600E in culture (PMID: 33158997). | 33158997 |
HRAS wild-type | rhabdomyosarcoma | sensitive | Rigosertib | Preclinical - Cell culture | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis in HRAS wild-type rhabdomyosarcoma cells in culture (PMID: 33158997). | 33158997 |
NRAS Q61H | rhabdomyosarcoma | sensitive | Rigosertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis and cell cycle arrest in rhabdomyosarcoma cells harboring NRAS Q61H in culture, and delayed tumor growth in cell line xenograft models (PMID: 33158997). | 33158997 |
NRAS wild-type | neuroblastoma | sensitive | Rigosertib | Preclinical - Cell culture | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis in NRAS wild-type neuroblastoma cells in culture (PMID: 33158997). | 33158997 |
NRAS Q61K | neuroblastoma | predicted - sensitive | Rigosertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis and cell cycle arrest in neuroblastoma cells harboring NRAS Q61K in culture, but did not significantly delay tumor growth in cell line xenograft models (PMID: 33158997). | 33158997 |
HRAS Q61K | rhabdomyosarcoma | sensitive | Rigosertib | Preclinical - Cell culture | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis and cell cycle arrest in rhabdomyosarcoma cells harboring HRAS Q61K in culture (PMID: 33158997). | 33158997 |
NRAS wild-type | rhabdomyosarcoma | sensitive | Rigosertib | Preclinical - Cell culture | Actionable | In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis in NRAS wild-type rhabdomyosarcoma cells in culture (PMID: 33158997). | 33158997 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|